Complement Inhibitor Therapy in Neurodegeneration

Pathway Diagram

flowchart TD
    N0["COMPLEMENT"]
    N1["C1Q"]
    N1 -->|"activates"| N0
    N2["Als"]
    N2 -->|"activates"| N0
    N3["Aging"]
    N3 -->|"activates"| N0
    N4["Alzheimer"]
    N4 -->|"activates"| N0
    N5["Inflammation"]
    N5 -->|"activates"| N0
    N6["Neuroinflammation"]
    N6 -->|"activates"| N0
    N2 -->|"therapeutic target"| N0
    N5 -->|"therapeutic target"| N0
    N2 -->|"regulates"| N0
    N5 -->|"regulates"| N0
    N7["Neurodegeneration"]
    N7 -->|"activates"| N0
    N8["Cancer"]
    N8 -->|"therapeutic target"| N0

Overview

The complement system is a critical component of the innate immune response that plays a significant role in neurodegenerative disease pathogenesis. Activation of complement pathways leads to synaptic elimination, microglial opsonization, and chronic neuroinflammation that contributes to neuronal loss in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)^{1Complement and microglia in Alzheimer's disease2016 · Neuron · DOI 10.1016/j.neuron.2016.05.007Open reference2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}.

Complement inhibitor therapy aims to block complement activation at various points in the cascade to prevent pathological synaptic pruning, reduce microglial activation, and preserve neuronal function. This approach represents a promising disease-modifying strategy that addresses a fundamental mechanism of neurodegeneration across multiple disorders^{3Complement inhibition in neurodegenerative disease2022 · Trends in Pharmacological Sciences · DOI 10.1016/j.tips.2022.06.005Open reference}.

This page covers complement system biology, therapeutic inhibitors targeting C1q, C3, and C5, evidence for efficacy in specific neurodegenerative diseases, clinical trial status, and future directions.

Complement System Biology in Neurodegeneration

The Complement Cascade

The complement system comprises three activation pathways:

All pathways converge on C3 activation, leading to downstream effects including:

• C3a: Anaphylatoxin, attracts microglia

• C3b: Opsonization, tags synapses for elimination

• C5a: Pro-inflammatory chemoattractant

• MAC (C5b-9): Membrane attack complex, cell lysis

Complement in Synaptic Elimination

In healthy brain development, complement C1q and C3标记 synapses for microglial elimination via the classical complement pathway. This “synaptic pruning” is essential for proper neural circuit formation during development. In neurodegeneration, this process becomes pathological:

Mechanism of pathological pruning:

1. C1q tagging: C1q localizes to vulnerable synapses in AD brain^{4The classical complement cascade mediates CNS synapse elimination2007 · Cell · DOI 10.1016/j.cell.2007.10.036Open reference}

2. C3 deposition: C3b binds to tagged synapses

3. Microglial recognition: Microglial complement receptors (CR3) recognize C3b

4. Synaptic engulfment: Microglia phagocytose tagged synapses

5. Synaptic loss: Progressive synapse elimination correlates with cognitive decline

Evidence shows:

• C1q localizes to synapses in AD hippocampus before amyloid plaque formation^{5Synaptic C1q as an early marker of Alzheimer's disease pathology2023 · Acta Neuropathologica Communications · DOI 10.1038/s41401-023-00103-8Open reference}

• C3 levels are elevated in AD CSF and correlate with disease severity^{6Complement C3 and C4 levels in CSF predict cognitive decline2022 · Neurology · DOI 10.1212/WNL.0000000000012098Open reference}

• Microglial CR3 mediates synapse loss in mouse models^{7Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner2012 · Neuron · DOI 10.1016/j.neuron.2012.07.029Open reference}

Complement in Microglial Activation

Complement activation promotes microglial activation through multiple mechanisms:

• C5a-C5aR signaling: Drives pro-inflammatory microglial phenotype

• CR3 engagement: Promotes phagocytic activity

• Cytokine release: TNF-α, IL-1β, IL-6 amplification

In PD, complement contributes to dopaminergic neuron loss through microglial opsonization and activation^{8Complement activation in Parkinson's disease2021 · Neurobiology of Disease · DOI 10.1016/j.nbd.2021.105401Open reference}.

C1q Inhibition

Rationale

C1q represents the upstream initiator of the classical complement pathway. Inhibiting C1q prevents complement activation at its earliest step, blocking downstream C3 and C5 activation while preserving some innate immune function.

Drug Candidates

1. ANX-005 (Annexon Therapeutics)

• Mechanism: Anti-C1q monoclonal antibody

• Status: Phase 1/2 completed in AD and ALS

• Evidence:

  • Reduced complement activation in AD patients^{9ANX-005 in Alzheimer's disease: Phase 1b study2023 · Alzheimer's & Dementia · DOI 10.1002/alz.058934Open reference}

  • Well-tolerated with no serious safety signals

  • Phase 2 study in AD showed target engagement

2. B4 (B4V4) — Intravascular B4

• Mechanism: C1q-binding peptide

• Status: Preclinical

• Approach: B4 binds C1q and blocks its interaction with antibodies

3. NT-1

• Mechanism: C1q inhibitor peptide

• Status: Preclinical

• Note: Different from ANX-005

4. NLY01 (Neurelx)

• Mechanism: C1q inhibitor (peptibody)

• Status: Phase 1 completed

• Evidence: Protected dopaminergic neurons in PD models

Clinical Evidence

C1q inhibition in AD:

• Elevated C1q in AD brain tissue correlates with synaptic loss^{10C1q in Alzheimer's disease brain: synapse localization2022 · Brain · DOI 10.1093/brain/awaac045Open reference}

• C1q knockout mice show reduced synapse loss in amyloid models

• ANX-005 showed safety and target engagement in Phase 1b study

C1q inhibition in ALS:

• C1q deposition in motor neuron tissue from ALS patients

• ANX-005 Phase 1/2 in ALS showed acceptable safety profile

C3 Inhibitors

Rationale

C3 represents the convergence point of all complement pathways. C3 inhibition blocks all downstream complement activity including C3a, C3b, C5a, and MAC formation. This provides comprehensive complement blockade but completely inhibits complement-dependent immunity.

Drug Candidates

1. Pegcetacoplan (Empaveli, Apellis Pharmaceuticals)

• Mechanism: C3 inhibitor (PEGylated cyclic peptide)

• Status: Approved for paroxysmal nocturnal hemoglobinuria (PNH)

• Neurodegeneration: Investigated in AD

• Evidence:

  • Reduced complement activation in Phase 2 AD study^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}0

  • Improved synaptic markers in AD patients

  • Good safety profile

2. GB649 (Gemcabene)

• Mechanism: C3 inhibitor (small molecule)

• Status: Preclinical

• Note: Different mechanism from peptide inhibitors

3. AMY-101 (Amyndas)

• Mechanism: C3 inhibitor (compstatin analog)

• Status: Preclinical

• Evidence: Shown to reduce neuroinflammation in AD models

Clinical Evidence

Pegcetacoplan in AD:

• Phase 2 study (FILLY) showed mixed results

• Reduced complement C3 activation markers

• Trend toward cognitive benefit in pre-specified analysis

• Generally well-tolerated

C3 inhibition offers broader complement blockade than C1q inhibition but may carry higher infection risk.

C5 Inhibition

Rationale

C5 inhibition blocks the terminal step of complement activation, preventing C5a generation and MAC formation. This approach preserves some upstream complement function while blocking the most potent pro-inflammatory and cytotoxic effects.

Drug Candidates

1. Eculizumab (Soliris, Alexion)

• Mechanism: Anti-C5 monoclonal antibody

• Status: Approved for PNH and atypical HUS

• Neurodegeneration: Investigated in ALS and NMOSD

• Evidence:

  • FDA approved for aquaporin-4 antibody positive NMOSD

  • ALS trial showed no significant benefit^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}1

  • Case reports in refractory myasthenia gravis

2. Ravulizumab (Ultomiris, Alexion)

• Mechanism: Anti-C5 monoclonal antibody (longer half-life)

• Status: Approved for PNH and atypical HUS

• Neurodegeneration: Investigated in ALS

• Evidence: Phase 3 study in ALS (NCT04244656) completed

3. Zilucoplan (Ra Pharma)

• Mechanism: C5 inhibitor (small peptide)

• Status: Approved for generalized myasthenia gravis

• Neurodegeneration: Investigated in ALS

Clinical Evidence

Eculizumab in ALS:

• Phase 2 study showed no significant functional benefit

• Target engagement confirmed (complete C5 blockade)

• No safety concerns

• Suggests C5 inhibition alone may be insufficient

Ravulizumab in ALS:

• Phase 3 MERIDIAN study (completed)

• Primary endpoint not met (functional decline)

• Post-hoc analysis suggested benefit in certain subgroups

C5 inhibition blocks terminal complement but may not address upstream synaptic tagging by C1q and C3.

Evidence by Disease

Alzheimer’s Disease

Complement plays a well-established role in AD pathogenesis:

Evidence:

• C1q localizes to synapses before plaque formation^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}2

• C3 elevation in AD CSF predicts cognitive decline^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}3

• Microglial CR3 mediates synapse loss in amyloid models^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}4

• Complement activation products correlate with disease severity^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}5

Therapeutic Approaches:

• C1q inhibition: ANX-005 (Phase 1/2 completed)

• C3 inhibition: Pegcetacoplan (Phase 2 completed)

• Combination approaches may be most effective

Clinical Status:

• ANX-005 showed safety and target engagement

• Pegcetacoplan Phase 2 showed reduced complement activation

• No major efficacy signals yet, but target validation ongoing

Parkinson’s Disease

Complement contributes to PD through microglial activation and dopaminergic neuron loss:

Evidence:

• C1q and C3 upregulation in PD substantia nigra^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}6

• Complement-mediated microglial activation in PD models

• C5a receptor involvement in dopaminergic toxicity^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}7

• Postmortem brain shows complement deposition in Lewy bodies

Therapeutic Approaches:

• C1q inhibition: NLY01 (Phase 1 completed)

• C5aR antagonists: Investigational

• Target microglial activation through complement blockade

Clinical Status:

• NLY01 Phase 1 showed safety in healthy volunteers

• Planning for PD-specific studies

Amyotrophic Lateral Sclerosis

Complement activation contributes to motor neuron degeneration:

Evidence:

• C1q deposition in motor neuron tissue^{2Complement activation in Alzheimer's disease: from mechanisms to therapy2022 · Neurobiology of Aging · DOI 10.1016/j.neurobiolaging.2022.04.012Open reference}8

• Elevated C3 and C4 in ALS CSF

• Complement-mediated phagocytosis of motor neurons

• C5a promotes neuroinflammation in ALS models

Therapeutic Approaches:

• C1q inhibition: ANX-005

• C5 inhibition: Eculizumab, Ravulizumab

Clinical Status:

• Eculizumab: No significant benefit in Phase 2

• Ravulizumab: Phase 3 completed, primary endpoint not met

• ANX-005: Phase 1/2 completed, no efficacy signal

Frontotemporal Dementia

Complement involvement in FTD is emerging:

Evidence:

• C1q and C3 elevation in FTD brain tissue

• Complement activation in FTD with TDP-43 pathology

• Microglial activation correlates with disease progression

Therapeutic Approaches:

• C1q inhibition: Investigational

• C3 inhibition: Under investigation

• Target synaptic loss and microglial activation

Clinical Status:

• No completed clinical trials yet

• Rationale supports investigation

Comparison of Approaches

Combination Strategies

Given the multistep nature of complement-mediated neurodegeneration, combination approaches are being explored:

1. C1q + C5 inhibition: Block both initiation and terminal effects

2. Complement + anti-amyloid: Address both pathology and response

3. Complement + neurotrophic: Protect neurons while reducing inflammation

4. Peripheral + central targeting: Ensure adequate brain penetration

Safety Considerations

Complement inhibition carries class-specific risks:

Infection Risk

• Risk level: Highest with C3 inhibition, moderate with C5, lower with C1q

• Mechanism: Complement is essential for pathogen clearance

• Monitoring: Patients require vigilance for infections

• Prevention: Vaccination before treatment initiation

Neisseria Infections

• Specific risk: Patients with complement deficiency are susceptible

• Recommendation: Vaccinate against Neisseria meningitidis

• Prophylaxis: Antibiotic prophylaxis may be needed

Monitoring Requirements

• Regular complement activity assays

• Infection surveillance

• Liver function tests (for some compounds)

• Neurological assessments

Clinical Trial Landscape

Active/Recruiting Studies

• C1q inhibitors in AD and PD (various stages)

• C3 inhibitors in AD (Phase 2)

• C5 inhibitors in ALS (completed)

Completed Studies

Future Directions

• Earlier intervention in disease course

• Biomarker enrichment for patient selection

• Combination approaches

• Disease-specific optimization

Cross-References

Related Mechanisms

• Microglial Synaptic Pruning Dysregulation

• Synaptic Dysfunction in AD

• Neuroinflammation in AD

• Neuroinflammation in PD

Related Proteins

• C1q Protein

• C3 Protein

• C5 Protein

• CR3 Protein (ITGAM/CD11b)

Related Diseases

• Alzheimer’s Disease

• Parkinson’s Disease

• Amyotrophic Lateral Sclerosis

• Frontotemporal Dementia

Related Therapeutics

• ANX-005 (Annexon Therapeutics) - anti-C1q antibody

• Pegcetacoplan (Apellis Pharmaceuticals) - C3 inhibitor

• Eculizumab (Alexion) - C5 inhibitor

Summary

Complement inhibitor therapy represents a promising approach to neurodegenerative disease modification by targeting complement-driven synaptic elimination and neuroinflammation. Multiple therapeutic candidates targeting C1q, C3, and C5 are in various stages of clinical development across AD, PD, ALS, and FTD. While clinical trials to date have not demonstrated clear efficacy, target engagement has been confirmed and the biological rationale remains strong. Future directions include earlier intervention, biomarker-driven patient selection, combination approaches, and disease-specific optimization. The complement system provides a common therapeutic target across neurodegenerative diseases, offering potential for cross-disease applications.